Evoke Pharma Inc (EVOK)
0.549
+0.08
(+16.81%)
USD |
NASDAQ |
Apr 17, 16:00
Evoke Pharma Gross Profit Margin (Quarterly): 96.48% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 96.48% |
| September 30, 2023 | 97.77% |
| June 30, 2023 | 94.93% |
| March 31, 2023 | 93.76% |
| December 31, 2022 | 76.13% |
| September 30, 2022 | 89.21% |
| June 30, 2022 | 85.32% |
| Date | Value |
|---|---|
| March 31, 2022 | 94.56% |
| December 31, 2021 | 62.09% |
| September 30, 2021 | 93.72% |
| June 30, 2021 | 71.16% |
| March 31, 2021 | 28.39% |
| December 31, 2020 | -276.7% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-276.7%
Minimum
Dec 2020
97.77%
Maximum
Sep 2023
54.37%
Average
89.21%
Median
Sep 2022
Gross Profit Margin (Quarterly) Benchmarks
| Eton Pharmaceuticals Inc | 49.64% |
| NovaBay Pharmaceuticals Inc | 48.70% |
| Palatin Technologies Inc | 95.20% |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | -1.18K% |
| Return on Assets | -85.08% |
| Return on Invested Capital | -137.7% |
| Profit Margin (Quarterly) | -118.6% |
| Operating Margin (Quarterly) | -112.6% |
| Return on Net Operating Assets | -405.7% |